Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry.


Malavasi V. L., Vitolo M., Proietti M., Diemberger I., Fauchier L., Marin F., ...Daha Fazla

European journal of clinical investigation, cilt.52, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1111/eci.13773
  • Dergi Adı: European journal of clinical investigation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: all-cause death, atrial fibrillation, cancer, malignancy, NOACs, registry, DIRECT ORAL ANTICOAGULANTS, BLEEDING COMPLICATIONS, ACTIVE CANCER, MANAGEMENT, WARFARIN, SAFETY, RISK, THROMBOEMBOLISM, GUIDELINES, EFFICACY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: The management of patients with atrial fibrillation (AF) and malignancy is challenging given the paucity of evidence supporting their appropriate clinical management.